STEAP1 and neoplasm: Tumor uptake was higher in mice administered 89Zr–anti-TENB2 or 89Zr–anti-STEAP1 compared to mice given the control mAb 89Zr–anti-gD (p < 0.05); the exception was 89Zr-anti-STEAP1 uptake in LuCaP96.1 tumors which was no higher than control.